This application is being submitted to PA-18-591 in accordance with NOT-OD-18-195. Down syndrome (DS) is the major cause of intellectual disability in humans and it is estimated there are over 300,000 individuals with this genetic disorder in the United States. Virtually all DS individuals have sufficient neuropathology for a diagnosis of Alzheimer disease (AD) in their 40th year. However, dementia may not develop until up to a decade later and some people remain cognitively intact. Imaging studies reveal early neuropathology within the striatum and frontal lobes. Given these regions are involved in motor and cognitive function, we hypothesize that gait will be associated with changes in cognition and prodromal dementia. We will follow up with an initial cohort of DS individuals who had gait assessed three years ago to assess whether the degree of change in gait associates with prodromal dementia. Next, we will use a dual-task gait paradigm to elucidate subtle gait impairment and compare spatial and temporal gait characteristics from people with DS over a wide range of ages. Finally, we will use structural neuroimaging to identify underlying neural substrates associated with changes in gait and prodromal dementia. Determining whether gait indicates early pathogenesis of AD in DS will initiate early treatment, improving quality of life. Furthermore, earlier detection of prodromal dementia will facilitate research investigating pathogenesis and subsequently may provide novel targets for a preventative approach to slow or halt the development of AD neuropathology.
The proposed study will use gait identify early clinical signs of dementia reflecting Alzheimer disease (AD) in adults with Down syndrome (DS). Using magnetic resonance imaging and the GAITRite system to quantitatively measure gait, we will identify whether matter integrity losses are associated with gait and whether those regions are associated with early dementia symptoms. Identifying dementia earlier and resilience indicators provides opportunities to better track the progression of AD in DS and develop targeted interventions to improve the quality of life of DS individuals who are vulnerable to neurodegeneration.
Showing the most recent 10 out of 42 publications
